For the year ending 2025-12-31, MRVI had -$105,509K decrease in cash & cash equivalents over the period. -$70,722K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -230,762 |
| Depreciation | 23,558 |
| Amortization of intangible assets | 27,951 |
| Amortization of operating lease right-of-use assets | 8,963 |
| Amortization of deferred financing costs | 1,654 |
| Stock-based compensation expense | 30,174 |
| Loss on extinguishment of debt | 0 |
| Deferred income taxes | -20 |
| Change in estimated fair value of contingent consideration | 0 |
| Impairment | 84,597 |
| Revaluation of liabilities under the tax receivable agreement | 0 |
| Acquisition related tax adjustment | 4,082 |
| Other | -212 |
| Accounts receivable | -12,816 |
| Inventory | -7,999 |
| Prepaid expenses and other current assets | -1,626 |
| Other assets | -181 |
| Accounts payable | -7,347 |
| Accrued expenses and other current liabilities | -4,626 |
| Other long-term liabilities | -18,631 |
| Net cash (used in) provided by operating activities | -57,573 |
| Cash paid for acquisitions of a business, net of cash acquired | 18,990 |
| Purchases of property and equipment | 13,149 |
| Proceeds from government assistance allocated to property and equipment | 734 |
| Other investing activities, net | 0 |
| Net cash used in investing activities | -31,405 |
| Refunds (distributions) for tax liabilities to non-controlling interests holder | -10 |
| Principal repayments of long-term debt | 5,440 |
| Financing costs paid to acquire long-term debt | 0 |
| Proceeds from interest rate cap agreement | 1,375 |
| Payments of acquisition related contingent consideration and consideration holdback | 6,800 |
| Payments pursuant to the tax receivable agreement | 0 |
| Other financing activities, net | -5,644 |
| Net cash used in financing activities | -16,499 |
| Effects of exchange rate changes on cash | -32 |
| Net decrease in cash and cash equivalents | -105,509 |
| Cash and cash equivalents, beginning of period | 322,399 |
| Cash and cash equivalents, end of period | 216,890 |
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)